BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 2647187)

  • 1. GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.
    Devereaux S; Linch DC; Gribben JG; McMillan A; Patterson K; Goldstone AH
    Bone Marrow Transplant; 1989 Jan; 4(1):49-54. PubMed ID: 2647187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
    Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
    Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
    Greenberg P; Advani R; Keating A; Gulati SC; Nimer S; Champlin R; Karanes C; Gorin NC; Powles RL; Smith A; Lamborn K; Cuffie C
    Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte-macrophage colony-stimulating factor after autologous marrow transplantation for Hodgkin's disease.
    Klingemann HG; Wilkie-Boyd K; Rubin A; Onetto N; Nantel SH; Barnett MJ; Reece DE; Shepherd JD; Phillips GL
    Biotechnol Ther; 1994; 5(1-2):1-13. PubMed ID: 7703829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapy.
    Spitzer G; Deisseroth A; Ventura G; Jagannath S; Fogel B; Taylor K; Huan S; Dunphy F; Dicke K; Souza L
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():249-59; discussion 259-61. PubMed ID: 1691246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
    Schmitz N; Dreger P; Zander AR; Ehninger G; Wandt H; Fauser AA; Kolb HJ; Zumsprekel A; Martin A; Hecht T
    Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human granulocyte-macrophage colony stimulating factor (rh GM-CSF) after bone marrow transplantation.
    Link H; Freund M; Kirchner H; Stoll M; Schmid H; Bucsky P; Seidel J; Schulz G; Schmidt RE; Riehm H
    Behring Inst Mitt; 1988 Aug; (83):313-9. PubMed ID: 3071346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.
    Khwaja A; Goldstone AH; Linch DC
    Bone Marrow Transplant; 1995 Feb; 15(2):313-5. PubMed ID: 7773224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
    Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
    Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
    Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
    Smith RJ; Sweetenham JW
    Exp Hematol; 1995 Dec; 23(14):1581-8. PubMed ID: 8542950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.
    Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A
    Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant GM-CSF in patients with poor graft function after bone marrow transplantation.
    Klingemann HG; Eaves AC; Barnett MJ; Reece DE; Shepherd JD; Belch AR; Brandwein JM; Langleben A; Koch PA; Phillips GL
    Clin Invest Med; 1990 Apr; 13(2):77-81. PubMed ID: 2191816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
    Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
    Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.
    Taylor KM; Jagannath S; Spitzer G; Spinolo JA; Tucker SL; Fogel B; Cabanillas FF; Hagemeister FB; Souza LM
    J Clin Oncol; 1989 Dec; 7(12):1791-9. PubMed ID: 2479719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.